Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cell Reprogramming Market size was over USD 405.62 million in 2024 and is anticipated to cross USD 1.15 billion by 2037, witnessing more than 8.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cell reprogramming is estimated at USD 434.58 million.
The reason behind the growth is the rising burden of cancer across the globe. Developing nations may bear a disproportionate share of the cost of cancer incidence, morbidity, and mortality owing to rising levels of air pollution, unhealthy diets, drinking alcohol, smoking, and not moving around much. According to the World Health Organization (WHO), it is anticipated that there will be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022.
The growing advancements in technology are believed to fuel market growth. For instance, researchers have reported using a cell reprogramming technique to create neural networks that mimic distinct features of human cells, which could facilitate the development of new treatments for neuropathies.
Cell Reprogramming Sector: Growth Drivers and Challenges
Growth Drivers
- Growing popularity of personalized medicine - By first evaluating the safety of already-approved medications on reprogrammed patient cells in a customized way before they are administered, reprogramming may help precision medicine, which seeks to deliver individualized medical treatment.
Additionally, every patient has different medical requirements; therefore, generalized medical treatment may not be suitable for all patients. Personalized medicine treats patients in a very specific manner, which is more effective and targeted. - Surging prevalence of neurodegenerative diseases - Age-related neurodegenerative disorders and other late-onset diseases have been well modeled in cell culture to assist researchers in their studies of the aging process in addition to helping them create new therapeutic approaches. As per the World Health Organization (WHO), currently, about 55 million individuals globally suffer from dementia, with more than 60% residing in low- and middle-income nations.
- Increasing geriatric population - Reprogramming possesses the amazing capacity to undo some cellular and molecular traits linked to aging and can also improve the comprehension of human aging mechanisms and aid in the discovery of anti-aging drugs. For instance, more than 770 million individuals worldwide were 65 years of age or older in 2022, making up about 9% of the world's population. In addition, there are various advantages to cell reprogramming, such as the ability to regenerate damaged tissues and the huge scope for future therapeutic applications that boost the market growth of cell reprogramming.
Challenges
- Stringent regulatory requirements - Adhering to strict and durable conditions for cell culture is necessary for iPS cells and cell reprogramming to produce iPSCs of superior quality for use in medicinal settings. The strict regulatory requirements hinder the market growth of cell programming.
- Technical complexity may increase the need for specialized expertise and limit its accessibility to researchers with a lack of resources.
- The high cost of cell reprogramming may limit its adoption and hamper market growth.
Cell Reprogramming Market: Key Insights
Cell Reprogramming Segmentation
Product Type (Induced Pluripotent Stem Cells, Adult Stem Cells, Human Embryonic Stem Cells, Small Embryonic Like Stem Cells)
The induced pluripotent stem cell segment in the cell reprogramming market is estimated to gain a robust revenue share of 45% in the coming years, owing to the growing usage by scientists and researchers. Induced pluripotent stem cells are used by modern scientists and researchers to investigate human development and have been applied to numerous scientific investigations and clinical trials, such as those involving disease modeling, regenerative medicine, drug cytotoxicity, and discovery studies.
Also, the development of iPSCs has revolutionized stem cell research and created exciting new opportunities for improving cancer treatment, understanding tumor progression, and cell treatment. Moreover, there is a lot of optimism for the therapeutic use of induced pluripotent stem cells (iPSCs) in several disorders, as researchers may now address disease characteristics and how they progress in a cell culture plate by using pathogenic cells produced from patient cells.
End-Users (Hospitals, Research Organizations, Toxicity Test)
The research organization segment in the cell reprogramming market is set to garner a notable share in coming years. For scientists doing stem cell research, superior cell reprogramming techniques were created, a fascinating field of biomedical engineering study involving the direct conversion of an adult cell from one type to another. For instance, more information regarding naïve stem cell reprogramming has been made available to researchers from the Babraham Institute's Epigenetics research group that outlines the crucial regulators of reprogramming for a more effective method of producing human naïve pluripotent stem cells.
Our in-depth analysis of the global cell reprogramming market includes the following segments:
|
Product Type |
|
|
End-Users |
|
|
Derived Cell Types |
|
|
Application |
|
|
Reprogramming Type |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCell Reprogramming Industry - Regional Synopsis
North American Market Forecast
North America industry is set to hold largest revenue share of 44% by 2037, propelled by the growing adoption of cloud-based solutions. Cloud computing is becoming increasingly popular in the United States since it greatly improves communication between patients, providers, and stakeholders in the healthcare industry. For instance, by 2026, more than 65% of all hospitals and health systems in the US will probably have implemented a cloud-based supply chain management strategy, which will aid in improving decision-making, increasing agility and efficiency, and streamlining procedures. This may drive the demand for cell reprogramming as researchers extensively rely on cloud platforms to support their studies.
APAC Market Statistics
The Asia Pacific cell reprogramming market is estimated to be the second largest during the forecast timeframe, led by the growing advancements in biomedical research. Moreover, the substantial investments made by the Indian government in biomedical engineering research and development are opening up more opportunities for biomedical research, which is currently being redefined by groundbreaking developments in gene- and cell-based treatment.
In addition, the Indian government has expressed interest in advancing stem cells and regenerative medicine, though the area of regenerative medicine is still in its infancy. However, there have been various encouraging advancements and interest in innovation and entrepreneurship.
Companies Dominating the Cell Reprogramming Landscape
- Bio-Techne
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Human Longevity Inc.
- Lineage Cell Therapeutics
- Mesoblast
- Advanced Cell Technology Inc
- Lonza
- STEMCELL Technologies Inc.
- Astellas Pharma Inc.
- ALSTEM
- Mogrify Limited
In the News
- Mogrify Limited - Mogrify Limited and Astellas Pharma Inc. announced a collaboration to conduct research on in vivo regenerative medicines approaches to address sensorineural hearing loss. The collaboration will seek to recognize novel combinations of factors that are included in cell differentiation to generate new cochlear hair cells.
- Mesoblast - Mesoblast announced a partnership with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a clinical investigation and carry out the study that will assess Ryoncil in individuals 12 years of age and older who have not responded to first-line therapies such as corticosteroids or ruxolitinib.
Author Credits: Radhika Pawar
- Report ID: 5835
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
